A targeted approach for congenital cytomegalovirus screening within newborn hearing screening

Karen B. Fowler, Faye P. McCollister, Diane L. Sabo, Angela G. Shoup, Kris E. Owen, Julie L. Woodruff, Edith Cox, Lisa S. Mohamed, Daniel I. Choo, Suresh B. Boppana

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

BACKGROUND AND OBJECTIVE: Congenital cytomegalovirus (cCMV) infection remains a leading cause of childhood hearing loss. Currently universal CMV screening at birth does not exist in the United States. An alternative approach could be testing infants who do not pass their newborn hearing screening (NHS) for cCMV. This study was undertaken to evaluate whether a targeted approach will identify infants with CMV-related sensorineural hearing loss (SNHL). METHODS: Infants born at 7 US medical centers received NHS and were also screened for cCMV while in the newborn nursery. Infants who tested positive for CMV received further diagnostic audiologic evaluations to identify or confirm hearing loss. RESULTS: Between 2007 and 2012, 99 945 newborns were screened for both hearing impairment and cCMV. Overall, 7.0% of CMV-positive infants did not pass NHS compared with 0.9% of CMV-negative infants (P < .0001). Among the cCMV infants who failed NHS, diagnostic testing confirmed that 65% had SNHL. In addition, 3.6% of CMV-infected infants who passed their NHS had SNHL confirmed by further evaluation during early infancy. NHS in this cohort identified 57% of all CMV-related SNHL that occurred in the neonatal period. CONCLUSIONS: A targeted CMV approach that tests newborns who fail their NHS identified the majority of infants with CMV-related SNHL at birth. However, 43% of the infants with CMVrelated SNHL in the neonatal period and cCMV infants who are at risk for late onset SNHL were not identified by NHS.

Original languageEnglish (US)
Article numbere20162128
JournalPediatrics
Volume139
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

Cytomegalovirus
Hearing
Sensorineural Hearing Loss
Newborn Infant
Hearing Loss
Parturition
Nurseries
Cytomegalovirus Infections

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Fowler, K. B., McCollister, F. P., Sabo, D. L., Shoup, A. G., Owen, K. E., Woodruff, J. L., ... Boppana, S. B. (2017). A targeted approach for congenital cytomegalovirus screening within newborn hearing screening. Pediatrics, 139(2), [e20162128]. https://doi.org/10.1542/peds.2016-2128

A targeted approach for congenital cytomegalovirus screening within newborn hearing screening. / Fowler, Karen B.; McCollister, Faye P.; Sabo, Diane L.; Shoup, Angela G.; Owen, Kris E.; Woodruff, Julie L.; Cox, Edith; Mohamed, Lisa S.; Choo, Daniel I.; Boppana, Suresh B.

In: Pediatrics, Vol. 139, No. 2, e20162128, 01.02.2017.

Research output: Contribution to journalArticle

Fowler, KB, McCollister, FP, Sabo, DL, Shoup, AG, Owen, KE, Woodruff, JL, Cox, E, Mohamed, LS, Choo, DI & Boppana, SB 2017, 'A targeted approach for congenital cytomegalovirus screening within newborn hearing screening', Pediatrics, vol. 139, no. 2, e20162128. https://doi.org/10.1542/peds.2016-2128
Fowler, Karen B. ; McCollister, Faye P. ; Sabo, Diane L. ; Shoup, Angela G. ; Owen, Kris E. ; Woodruff, Julie L. ; Cox, Edith ; Mohamed, Lisa S. ; Choo, Daniel I. ; Boppana, Suresh B. / A targeted approach for congenital cytomegalovirus screening within newborn hearing screening. In: Pediatrics. 2017 ; Vol. 139, No. 2.
@article{bba74cc4245146e98167dda1771249b0,
title = "A targeted approach for congenital cytomegalovirus screening within newborn hearing screening",
abstract = "BACKGROUND AND OBJECTIVE: Congenital cytomegalovirus (cCMV) infection remains a leading cause of childhood hearing loss. Currently universal CMV screening at birth does not exist in the United States. An alternative approach could be testing infants who do not pass their newborn hearing screening (NHS) for cCMV. This study was undertaken to evaluate whether a targeted approach will identify infants with CMV-related sensorineural hearing loss (SNHL). METHODS: Infants born at 7 US medical centers received NHS and were also screened for cCMV while in the newborn nursery. Infants who tested positive for CMV received further diagnostic audiologic evaluations to identify or confirm hearing loss. RESULTS: Between 2007 and 2012, 99 945 newborns were screened for both hearing impairment and cCMV. Overall, 7.0{\%} of CMV-positive infants did not pass NHS compared with 0.9{\%} of CMV-negative infants (P < .0001). Among the cCMV infants who failed NHS, diagnostic testing confirmed that 65{\%} had SNHL. In addition, 3.6{\%} of CMV-infected infants who passed their NHS had SNHL confirmed by further evaluation during early infancy. NHS in this cohort identified 57{\%} of all CMV-related SNHL that occurred in the neonatal period. CONCLUSIONS: A targeted CMV approach that tests newborns who fail their NHS identified the majority of infants with CMV-related SNHL at birth. However, 43{\%} of the infants with CMVrelated SNHL in the neonatal period and cCMV infants who are at risk for late onset SNHL were not identified by NHS.",
author = "Fowler, {Karen B.} and McCollister, {Faye P.} and Sabo, {Diane L.} and Shoup, {Angela G.} and Owen, {Kris E.} and Woodruff, {Julie L.} and Edith Cox and Mohamed, {Lisa S.} and Choo, {Daniel I.} and Boppana, {Suresh B.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1542/peds.2016-2128",
language = "English (US)",
volume = "139",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "2",

}

TY - JOUR

T1 - A targeted approach for congenital cytomegalovirus screening within newborn hearing screening

AU - Fowler, Karen B.

AU - McCollister, Faye P.

AU - Sabo, Diane L.

AU - Shoup, Angela G.

AU - Owen, Kris E.

AU - Woodruff, Julie L.

AU - Cox, Edith

AU - Mohamed, Lisa S.

AU - Choo, Daniel I.

AU - Boppana, Suresh B.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - BACKGROUND AND OBJECTIVE: Congenital cytomegalovirus (cCMV) infection remains a leading cause of childhood hearing loss. Currently universal CMV screening at birth does not exist in the United States. An alternative approach could be testing infants who do not pass their newborn hearing screening (NHS) for cCMV. This study was undertaken to evaluate whether a targeted approach will identify infants with CMV-related sensorineural hearing loss (SNHL). METHODS: Infants born at 7 US medical centers received NHS and were also screened for cCMV while in the newborn nursery. Infants who tested positive for CMV received further diagnostic audiologic evaluations to identify or confirm hearing loss. RESULTS: Between 2007 and 2012, 99 945 newborns were screened for both hearing impairment and cCMV. Overall, 7.0% of CMV-positive infants did not pass NHS compared with 0.9% of CMV-negative infants (P < .0001). Among the cCMV infants who failed NHS, diagnostic testing confirmed that 65% had SNHL. In addition, 3.6% of CMV-infected infants who passed their NHS had SNHL confirmed by further evaluation during early infancy. NHS in this cohort identified 57% of all CMV-related SNHL that occurred in the neonatal period. CONCLUSIONS: A targeted CMV approach that tests newborns who fail their NHS identified the majority of infants with CMV-related SNHL at birth. However, 43% of the infants with CMVrelated SNHL in the neonatal period and cCMV infants who are at risk for late onset SNHL were not identified by NHS.

AB - BACKGROUND AND OBJECTIVE: Congenital cytomegalovirus (cCMV) infection remains a leading cause of childhood hearing loss. Currently universal CMV screening at birth does not exist in the United States. An alternative approach could be testing infants who do not pass their newborn hearing screening (NHS) for cCMV. This study was undertaken to evaluate whether a targeted approach will identify infants with CMV-related sensorineural hearing loss (SNHL). METHODS: Infants born at 7 US medical centers received NHS and were also screened for cCMV while in the newborn nursery. Infants who tested positive for CMV received further diagnostic audiologic evaluations to identify or confirm hearing loss. RESULTS: Between 2007 and 2012, 99 945 newborns were screened for both hearing impairment and cCMV. Overall, 7.0% of CMV-positive infants did not pass NHS compared with 0.9% of CMV-negative infants (P < .0001). Among the cCMV infants who failed NHS, diagnostic testing confirmed that 65% had SNHL. In addition, 3.6% of CMV-infected infants who passed their NHS had SNHL confirmed by further evaluation during early infancy. NHS in this cohort identified 57% of all CMV-related SNHL that occurred in the neonatal period. CONCLUSIONS: A targeted CMV approach that tests newborns who fail their NHS identified the majority of infants with CMV-related SNHL at birth. However, 43% of the infants with CMVrelated SNHL in the neonatal period and cCMV infants who are at risk for late onset SNHL were not identified by NHS.

UR - http://www.scopus.com/inward/record.url?scp=85014091450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014091450&partnerID=8YFLogxK

U2 - 10.1542/peds.2016-2128

DO - 10.1542/peds.2016-2128

M3 - Article

C2 - 28049114

AN - SCOPUS:85014091450

VL - 139

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 2

M1 - e20162128

ER -